Quito, Ecuador and Aachen, Germany. October 1, 2015. The Grünenthal Group announces that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária, Brazilian Health Surveillance Agency). This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification.
“We are very pleased that our plant in Ecuador can now also be a full service supply partner for Brazil as it is already for Andean countries and the Mexican market. The ANVISA certification is another key milestone in demonstrating our high quality capabilities in global contract manufacturing”, states Alberto Grua, Member of the Corporate Executive Board of Grünenthal.
Tecnandina SA belongs to the Grünenthal Group, an international, research-based, privately owned pharmaceutical company headquartered in Aachen, Germany. The Grünenthal Group offers contract manufacturing from its five independent production plants throughout Europe and Latin America.
Biggest pharmaceutical manufacturer in Ecuador
Tecnandina, SA is the biggest pharmaceutical manufacturer in Ecuador and one of the few regional contract manufacturers with international quality standards.
Tecnandina is a full-service provider including galenic development capabilities.
Tecnandina manufactures and exports to 17 countries in Central and South America, Switzerland as well as the Andean countries and offers integral solutions in manufacturing for third parties.
Besides ANVISA, Tecnandina, SA also has INVIMA (Colombian Medicines Agency), EMA (European Medicines Agency), EU GMP, WHO GMP, GLP, OHSAS 18001: 2007 and ISO 14001: 2004 approvals.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Australia, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,200 employees are working for the Grünenthal Group worldwide. In 2014, Grünenthal achieved revenues of
- Grünenthal receives Brazilian ANVISA certification for Tecnandina production plant in Ecuador (pdf, 201.4 KB)
Phone +49 241 569-1616